Copyright
©The Author(s) 2024.
World J Clin Oncol. Jul 24, 2024; 15(7): 859-866
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.859
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.859
Table 3 Toxicity
| Symptom | Control group, No. of patients | Observation group, No. of patients | ||||||
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Leukopenia | 11 | 7 | 3 | 1 | 12 | 8 | 4 | 1 |
| Fatigue | 15 | 6 | 2 | 0 | 16 | 9 | 2 | 0 |
| Anemia | 14 | 5 | 1 | 0 | 15 | 6 | 1 | 0 |
| Nausea | 18 | 8 | 0 | 0 | 20 | 10 | 1 | 0 |
| Anorexia | 8 | 5 | 0 | 0 | 11 | 7 | 0 | 0 |
- Citation: Zhou SQ, Wan P, Zhang S, Ren Y, Li HT, Ke QH. Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma. World J Clin Oncol 2024; 15(7): 859-866
- URL: https://www.wjgnet.com/2218-4333/full/v15/i7/859.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i7.859